Medicale Corp.
MCLEdata completeness 63%5 fiscal years on fileData notes: no data for concept 'capex'; no data for concept 'totalDebt'
i. The business — what you’d actually own
| Figure | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Revenue | $01 | $01 | — | — | — |
| Net income | −$32,1522 | −$46,4193 | −$37,1384 | −$58,2135 | −$41,1535 |
| Operating cash flow | −$17,7526 | −$24,6197 | −$25,7398 | −$83,5859 | −$23,0089 |
| Capital expenditure | — | — | — | — | — |
| Free cash flow (derived) | — | — | — | — | — |
| Total debt | — | — | — | — | — |
| Cash & equivalents | $18,47510 | $011 | $15912 | $15912 | $012 |
| Diluted shares | 3.6M | 5.9M | 5.9M | 5.9M | 5.9M |
Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).
ii. Your slice — ownership made literal
If you owned
shares
Net assets behind them
−$0.24
your share of equity
Profit it earned you last year
−$0.07
Free cash flow it threw off
—
Debt you’d be carrying
—
10 shares is a claim on −$0.24 of net worth that earned you −$0.07 last year.
iii. Is this a good business?
Moat signal · return on equity
— avg · 5y
Not enough data in the filings for a return-on-capital reading.
seeing a moat in the numbers →Management signal · capital allocation
+64% shares · 5y
Share count is up 64% over 5 years — owners have been diluted. Worth asking what they got for it.
reading capital allocation →Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.
iv. What it’s worth — engine v0.1.0
DCF · Growth Exit 10Y
not applicable
only 0 years of FCF (need ≥3) — model not applicable
DCF · Growth Exit 5Y
not applicable
only 0 years of FCF (need ≥3) — model not applicable
Earnings Power Value
not applicable
normalized (5y-median) earnings non-positive — EPV undefined
Graham Number
not applicable
diluted EPS missing or non-positive — Graham Number undefined
Different models answer different questions — which to trust when →
Sources — the receipts
- 10-K · period ending 2021-09-30 · accession 0001683168-22-008165 (Revenues)
- 10-K · period ending 2021-09-30 · accession 0001683168-22-008165 (NetIncomeLoss)
- 10-K · period ending 2022-09-30 · accession 0001683168-24-000004 (NetIncomeLoss)
- 10-K · period ending 2023-09-30 · accession 0001683168-25-000327 (NetIncomeLoss)
- 10-K · period ending 2024-09-30 · accession 0001683168-26-000203 (NetIncomeLoss)
- 10-K · period ending 2021-09-30 · accession 0001683168-22-008165 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2022-09-30 · accession 0001683168-24-000004 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2023-09-30 · accession 0001683168-25-000327 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2024-09-30 · accession 0001683168-26-000203 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2021-09-30 · accession 0001683168-21-006349 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2022-09-30 · accession 0001683168-25-000327 (CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents)
- 10-K · period ending 2023-09-30 · accession 0001683168-26-000203 (CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents)